MA40662A1 - Anticorps contre tigit - Google Patents

Anticorps contre tigit

Info

Publication number
MA40662A1
MA40662A1 MA40662A MA40662A MA40662A1 MA 40662 A1 MA40662 A1 MA 40662A1 MA 40662 A MA40662 A MA 40662A MA 40662 A MA40662 A MA 40662A MA 40662 A1 MA40662 A1 MA 40662A1
Authority
MA
Morocco
Prior art keywords
antibodies
antibodies against
treatment
against tigit
fragments
Prior art date
Application number
MA40662A
Other languages
English (en)
Other versions
MA40662B1 (fr
Inventor
Mohan Srinivasan
Indrani Chakraborty
Mark F Maurer
Tseng-Hui Timothy Chen
Brigitte Devaux
Susan H Julien
Paul O Sheppard
Daniel F Ardourel
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA40662A1 publication Critical patent/MA40662A1/fr
Publication of MA40662B1 publication Critical patent/MA40662B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps, ou des fragments liant l'antigène de ceux-ci, qui se lient à un tigit (immunorécepteur de cellule t avec des domaines d'ig et d'itim) humain, ainsi que des utilisations de ces anticorps ou fragments dans des applications thérapeutiques, par exemple dans le traitement du cancer ou d'une infection virale chronique. Ce procédé de traitement comprend un traitement combiné avec des inhibiteurs d'autres interactions avec des récepteurs immunomodulateurs, comme une i
MA40662A 2014-12-23 2015-12-22 Anticorps contre tigit MA40662B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096267P 2014-12-23 2014-12-23
PCT/US2015/067332 WO2016106302A1 (fr) 2014-12-23 2015-12-22 Anticorps contre tigit

Publications (2)

Publication Number Publication Date
MA40662A1 true MA40662A1 (fr) 2020-06-30
MA40662B1 MA40662B1 (fr) 2020-12-31

Family

ID=55168435

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40662A MA40662B1 (fr) 2014-12-23 2015-12-22 Anticorps contre tigit

Country Status (23)

Country Link
US (3) US10189902B2 (fr)
EP (2) EP3237448A1 (fr)
JP (6) JP6180663B2 (fr)
KR (1) KR102644115B1 (fr)
CN (3) CN107207594B (fr)
AR (1) AR103268A1 (fr)
AU (2) AU2015369683C1 (fr)
BR (1) BR112017013385A2 (fr)
CL (1) CL2017001660A1 (fr)
CO (1) CO2017006989A2 (fr)
EA (1) EA039219B1 (fr)
IL (2) IL253013B (fr)
MA (1) MA40662B1 (fr)
MX (2) MX389267B (fr)
MY (1) MY187045A (fr)
PE (1) PE20171244A1 (fr)
PH (2) PH12022550771A1 (fr)
SG (2) SG11201705063VA (fr)
TN (1) TN2017000267A1 (fr)
TW (1) TWI708786B (fr)
UY (1) UY36471A (fr)
WO (1) WO2016106302A1 (fr)
ZA (2) ZA201704981B (fr)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126688A2 (fr) 2008-04-09 2009-10-15 Genentech, Inc. Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2957722C (fr) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anticorps anti-tigit
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
CN109069638B (zh) 2016-03-24 2022-03-29 璟尚生物制药公司 用于癌症治疗的三特异性抑制剂
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018024162A1 (fr) * 2016-08-03 2018-02-08 Sunshine Lake Pharma Co., Ltd. Protéine de fusion glp-1 comprenant une partie fc d'immunoglobuline mutée
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (fr) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Animal non humain génétiquement modifié avec un tigit humain ou chimérique
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
MX2019006072A (es) * 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
WO2018102746A1 (fr) * 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Molécules de liaison à l'antigène destinées à la tigit
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
EP3565839A4 (fr) * 2017-01-05 2021-04-21 Gensun Biopharma Inc. Antagonistes de régulateur de point de contrôle
CN111050788A (zh) * 2017-02-28 2020-04-21 西雅图基因公司 抗tigit抗体
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
JOP20190203A1 (ar) * 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
CN118892540A (zh) 2017-04-21 2024-11-05 新罗杰股份有限公司 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法
JP2020517699A (ja) * 2017-04-26 2020-06-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ジスルフィド結合の還元を最小限にする抗体製造法
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
SG11201909941QA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2019013132A (es) * 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
JP7348072B2 (ja) * 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
WO2018229163A1 (fr) 2017-06-14 2018-12-20 King's College London Méthodes d'activation des lymphocytes t v delta 2 négatifs gamma delta
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
BE1025333B1 (fr) * 2017-07-27 2019-01-23 Iteos Therapeutics S.A. Anticorps anti-tigit
WO2019023504A1 (fr) 2017-07-27 2019-01-31 Iteos Therapeutics Sa Anticorps anti-tigit
CN109425736B (zh) * 2017-08-25 2021-04-09 北京百普赛斯生物科技股份有限公司 一种检测pd-1抗体血药浓度的方法及试剂盒
CN111316091A (zh) 2017-09-07 2020-06-19 百时美施贵宝公司 通过毛细管电泳进行纯度测定的方法
US20200207867A1 (en) * 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
CN111051347B (zh) * 2017-09-29 2021-12-21 江苏恒瑞医药股份有限公司 Tigit抗体、其抗原结合片段及医药用途
US20190099506A1 (en) 2017-10-02 2019-04-04 Bristol-Myers Squibb Company Methods and compositions for deuterated biologics
CN111788225B (zh) * 2017-10-10 2025-02-18 赛诺菲 抗cd38抗体及与抗cd3和抗cd28抗体的组合
CA3084667A1 (fr) * 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Conjugue de construction d'anticorps-medicament pour le traitement de l'hepatite
WO2019122882A1 (fr) 2017-12-19 2019-06-27 Kymab Limited Anticorps bispécifique pour icos et pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
SG11202004158QA (en) * 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
TWI877769B (zh) * 2017-12-30 2025-03-21 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
JP7316284B2 (ja) * 2018-01-15 2023-07-27 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する抗体及びその多様体
SG11202004521QA (en) 2018-02-06 2020-06-29 I Mab Biopharma Us Ltd Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
US20200399376A1 (en) * 2018-02-26 2020-12-24 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
MX428543B (es) * 2018-02-28 2025-11-13 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
CN112020516B (zh) * 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
JP7351845B2 (ja) * 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
WO2019190931A1 (fr) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
CA3097625A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Proteines de fusion fc heterodimeres il-15/il-15ra et leurs utilisations
CA3097593A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Proteines de fusion heterodimeres ciblant pd-1 contenant des proteines de fusion fc d'il-15/il-15ra, domaines de liaison a l'antigene pd-1 et utilisations associees
SG11202011461TA (en) 2018-06-01 2020-12-30 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
JP2021529557A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
TWI754157B (zh) * 2018-07-25 2022-02-01 大陸商信達生物製藥（蘇州）有限公司 抗ｔｉｇｉｔ抗體及其用途
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
WO2020036987A1 (fr) 2018-08-13 2020-02-20 Signablok, Inc. Peptides et compositions pour traitement et imagerie ciblés
EP3841123A2 (fr) 2018-08-23 2021-06-30 Seagen Inc. Anticorps anti-tigit
CN113039201A (zh) * 2018-09-28 2021-06-25 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD137结合分子及其治疗用途
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
CA3116188A1 (fr) 2018-10-12 2020-04-16 Xencor, Inc. Proteines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polytherapies faisant intervenir celles-ci
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
MX2021005236A (es) * 2018-11-05 2021-06-18 Merck Sharp & Dohme Llc Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
WO2020127377A1 (fr) 2018-12-21 2020-06-25 Ose Immunotherapeutics Molécule bifonctionnelle anti-pd-1/il -7
SG11202107474RA (en) * 2019-01-07 2021-08-30 iTeos Belgium SA Anti-tigit antibodies
CN118894938A (zh) * 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン１８抗体及びそれらの使用の方法
MX2021009500A (es) * 2019-02-06 2021-09-08 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem1 y metodos relacionados.
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
CN109833480B (zh) * 2019-03-22 2021-09-07 中国科学院上海巴斯德研究所 靶向nk细胞免疫检查点治疗感染性疾病的方法
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
JP2022530496A (ja) * 2019-04-26 2022-06-29 ウーシー バイオロジクス アイルランド リミテッド Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
WO2020243570A1 (fr) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Signature de localisation cellulaire et polythérapie
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
CA3139641A1 (fr) * 2019-06-13 2020-12-17 Green Cross Corporation Anticorps dirige contre tigit et son utilisation
CA3143995A1 (fr) * 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anticorps anti-tigit
EP3990116A1 (fr) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFß1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
CA3146986A1 (fr) * 2019-07-15 2021-01-21 Shanghai Junshi Biosciences Co., Ltd. Anticorps anti-tigit et leur application
EP4008730A4 (fr) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. Anticorps anti-ctla4-anti-pd-1 bispécifique et ses utilisations
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
CA3149719A1 (fr) * 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Anticorps se liant a vista a un ph acide
TWI764291B (zh) 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
US20220340660A1 (en) * 2019-10-01 2022-10-27 Merck Sharp & Dohme Corp. Biomarkers for anti-tigit antibody treatment
EP4037700A2 (fr) 2019-10-03 2022-08-10 Xencor, Inc. Protéines de fusion fc hétérodimères d'il-12 ciblées
KR20220082007A (ko) * 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
CN114728171A (zh) * 2019-11-05 2022-07-08 默克专利有限公司 抗tigit抗体及其应用
WO2021093849A1 (fr) * 2019-11-14 2021-05-20 Wuxi Biologics (Shanghai) Co., Ltd. Nouvel anticorps dirigé contre tigit
MX2022006330A (es) * 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
WO2021113831A1 (fr) 2019-12-05 2021-06-10 Compugen Ltd. Anticorps anti-pvrig et anti-tigit pour élimination de tumeurs à base de cellules nk améliorées
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021139776A1 (fr) * 2020-01-10 2021-07-15 Shanghai Henlius Biotech, Inc. Anticorps anti-tigit, anticorps multispécifiques les comprenant, et leurs procédés d'utilisation
CN115052622B (zh) * 2020-01-21 2026-03-06 夏尔巴生物技术(杭州)有限公司 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
CA3167317C (fr) 2020-02-12 2025-05-27 Eli Lilly And Company Cristallisation d'anticorps ou de fragments de liaison à l'antigène
WO2021178611A1 (fr) * 2020-03-05 2021-09-10 Merck Sharp & Dohme Corp. Méthodes de traitement du cancer ou d'une infection faisant appel à une association d'un anticorps anti-pd-1, d'un anticorps anti-ctla4 et d'un anticorps anti-tigit
EP4119162A4 (fr) 2020-03-13 2023-08-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Protéine de liaison à pvgrig et ses utilisations médicales
CN113563470B (zh) * 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
EP4147053B1 (fr) 2020-05-07 2026-01-28 Institut Curie Antxr1 entant que biomarqueur des populations de fibroblastes immunosuppresseurs et son utilisation pour la prédiction de la réponse à l'immunothérapie
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2021238932A1 (fr) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 Anticorps multi-spécifique et son application
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
WO2021257124A1 (fr) 2020-06-18 2021-12-23 Genentech, Inc. Traitement avec des anticorps anti-tigit et des antagonistes de liaison à l'axe pd-1
CN111718415B (zh) * 2020-07-03 2021-02-23 上海洛启生物医药技术有限公司 一种抗tigit纳米抗体及其应用
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
EP4182458A2 (fr) * 2020-07-20 2023-05-24 Dana-Farber Cancer Institute, Inc. Méthodes et compositions pour le traitement et la prévention d'une infection par un coronavirus
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
EP4219553A4 (fr) * 2020-09-22 2024-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Anticorps anti-tigit et anticorps double et leur application
US20230365680A1 (en) 2020-09-30 2023-11-16 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
KR20230098221A (ko) * 2020-10-26 2023-07-03 아케소 바이오파마, 인크. 항-tigit 항체, 약학 조성물 및 이의 용도
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
US11028172B1 (en) * 2020-11-10 2021-06-08 Lepu Biopharma Co., Ltd. Anti-TIGIT antibodies and uses thereof
US20240002500A1 (en) * 2020-11-23 2024-01-04 Guangdong Fapon Biopharma Inc. Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof
WO2022112198A1 (fr) 2020-11-24 2022-06-02 Worldwide Innovative Network Procédé de sélection des thérapies optimales par points de contrôle immunitaire
CN114539418A (zh) * 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 双特异性抗体及其用途
TW202222345A (zh) * 2020-11-26 2022-06-16 大陸商信達生物製藥（蘇州）有限公司 包含抗ｔｉｇｉｔ／ｐｄ－１雙特異性抗體的製劑及其製備方法和用途
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
CN112538108B (zh) * 2020-12-24 2022-06-28 郑州大学 高亲和pvr突变体
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
CN116897202A (zh) * 2021-02-24 2023-10-17 科济生物医药（上海）有限公司 Tigit工程化细胞及其组合物
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
JP2024514816A (ja) 2021-04-09 2024-04-03 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体を用いるがんの治療方法
EP4320156A1 (fr) 2021-04-09 2024-02-14 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
CA3217279A1 (fr) 2021-05-04 2022-11-10 Olga Ignatovich Anticorps anti-tigit et leurs procedes d'utilisation
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
US12558406B2 (en) 2021-05-10 2026-02-24 Medimabbio Inc. Anti-TIGIT antibodies and use thereof
CN115466327B (zh) * 2021-06-10 2025-07-08 北京天广实生物技术股份有限公司 结合tigit的抗体及其用途
US20240352153A1 (en) * 2021-07-23 2024-10-24 Akeso Biopharma, Inc Pharmaceutical composition and use
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
KR20240046905A (ko) * 2021-08-20 2024-04-11 아케소 바이오파마, 인크. 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
MX2024003140A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Construcciones, composiciones y metodos de multabody optimizados.
US20240376207A1 (en) 2021-09-15 2024-11-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
JP2024535793A (ja) 2021-09-15 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用
WO2023056403A1 (fr) 2021-09-30 2023-04-06 Genentech, Inc. Méthodes de traitement de cancers hématologiques au moyen d'anticorps anti-tigit, d'anticorps anti-cd38 et d'antagonistes de liaison à l'axe pd-1
WO2023064958A1 (fr) 2021-10-15 2023-04-20 Compugen Ltd. Polythérapie avec des formulations d'anticorps anti-pvrig, d'anticorps anti-tigit et d'anticorps anti-pd-1
TW202323300A (zh) * 2021-11-10 2023-06-16 美商尖端免疫生醫公司 抗tigit構築體及其用途
WO2023108609A1 (fr) * 2021-12-17 2023-06-22 Shanghai Nigene Biological Science And Technology Co., Ltd. Anticorps anti-tigit et leurs utilisations
WO2023149978A1 (fr) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Biomarqueurs du cancer et traitements du cancer
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
CA3259975A1 (fr) 2022-03-15 2023-09-21 Compugen Ltd. Anticorps antagonistes de l'il-18bp et leur utilisation en monothérapie et polythérapie dans le traitement du cancer
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
US20260035460A1 (en) 2022-07-28 2026-02-05 Adeboye Henry ADEWOYE, MD Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
EP4565610A1 (fr) 2022-08-02 2025-06-11 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
CN117567619A (zh) * 2022-12-13 2024-02-20 华润生物医药有限公司 抗cd73抗体及其用途
CN116143923B (zh) * 2022-12-30 2025-11-11 合肥天港免疫药物有限公司 高亲和力tigit抗体及其应用
US20260217828A1 (en) 2023-01-31 2026-07-30 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024191807A1 (fr) 2023-03-10 2024-09-19 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-tigit
EP4681729A4 (fr) 2023-03-15 2026-07-15 Shanghai Mabgen Biotech Ltd Composition pharmaceutique contenant une protéine de liaison pd-1/pvrig/tigit et son utilisation médicale
WO2024196952A1 (fr) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Évaluation de sous-type de tumeur pour une thérapie anticancéreuse
CN118725130A (zh) * 2023-03-21 2024-10-01 上海赛金生物医药有限公司 抗ctla-4/抗tigit双特异性抗体及其应用
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2024200820A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Procédé de synthèse de nanoparticule lipidique ciblée et ses utilisations
CN121285743A (zh) * 2023-06-02 2026-01-06 艾库斯生物科学有限公司 用于预测癌症治疗功效的生物标志物
JP2026519841A (ja) * 2023-06-06 2026-06-18 ウーシー バイオロジクス アイルランド リミテッド 抗ｔｉｇｉｔ抗体及びその使用
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
CN121219319A (zh) * 2023-06-27 2025-12-26 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
WO2025068461A1 (fr) 2023-09-29 2025-04-03 Negio Therapeutics Dérivés de guanfacine et leur utilisation dans le traitement du cancer
WO2025068452A1 (fr) 2023-09-29 2025-04-03 Negio Therapeutics Dérivés du guanfacine et leur utilisation dans le traitement du cancer
WO2025132831A1 (fr) 2023-12-19 2025-06-26 Universite D'aix-Marseille Dérivés de n-hétéroaryle et leurs utilisations pour le traitement du cancer
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
KR102872375B1 (ko) * 2024-01-24 2025-10-24 메디맵바이오 주식회사 Tigit에 특이적으로 결합하는 항-tigit 항체, 상기 항체 및 인터루킨-10를 포함하는 융합 단백질 및 이들의 용도
WO2025242836A1 (fr) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molécules comprenant des lieurs de masquage et leurs utilisations pour le traitement de maladies et de troubles auto-immuns ou inflammatoires
WO2025242835A1 (fr) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molécules comprenant des lieurs de masquage et leurs utilisations pour le traitement du cancer
WO2025262250A1 (fr) 2024-06-20 2025-12-26 Negio Therapeutics Dérivés de guanfacine et leurs utilisations
WO2026068705A1 (fr) 2024-09-26 2026-04-02 Ose Immunotherapeutics Nanoparticules à base de lipides comprenant des domaines fc non glycosylés et leurs utilisations

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0401384B1 (fr) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CA2249195A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0970128A1 (fr) 1997-03-21 2000-01-12 Brigham And Women's Hospital Peptides immunotherapeutiques se liant a ctla-4
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
CA2323757C (fr) 1998-04-02 2011-08-02 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CA3016482A1 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
EP2277532A1 (fr) 2002-09-11 2011-01-26 Genentech, Inc. Nouvelles compositions et procédés pour le traitement de maladies liées au système immunitaire
CA2832136C (fr) 2002-09-27 2015-11-17 Xencor Variants fc optimises et methodes destinees a leur generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EA010654B1 (ru) 2004-11-23 2008-10-30 Пи Ай Пи Ко., Лтд. Вмонтированная в стену распределительная коробка водоснабжения
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
EP3683230A1 (fr) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions et procédés pour moduler les réponses immunologiques
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (fr) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
DE102007036200A1 (de) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
EP2190861A4 (fr) 2007-08-22 2011-03-30 Univ California Polypeptides de liaison activables et procédés d'identification et utilisation de ceux-ci
HRP20150074T1 (hr) 2007-10-01 2015-03-13 Bristol-Myers Squibb Company Humana antitijela koja se vežu za mezotelin i njihove uporabe
EP2229187A2 (fr) 2007-11-30 2010-09-22 Bristol-Myers Squibb Company Conjugués anticorps monoclonal-molécules partenaires dirigés contre la protéine tyrosine kinase 7 (ptk7)
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
WO2009073620A2 (fr) 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
WO2009079242A2 (fr) 2007-12-05 2009-06-25 Massachusetts Institute Of Technology Mutants d'immunoglobuline aglycosylée
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
AU2008353145B2 (en) 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009126688A2 (fr) * 2008-04-09 2009-10-15 Genentech, Inc. Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
CA2721202A1 (fr) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capables de se lier a des proteines seriques et composes, constructions et polypeptides les comprenant
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20100189727A1 (en) 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
IN2015DN02826A (fr) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (fr) 2009-10-28 2016-10-05 Newlink Genetics Corporation Dérivés imidazole comme inhibiteurs de l'ido
EP3279215B1 (fr) 2009-11-24 2020-02-12 MedImmune Limited Agents de liaison ciblés contre b7-h1
WO2011072204A1 (fr) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Souris fabriquant des anticorps à chaînes lourdes
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
EP3053932B1 (fr) 2010-02-19 2020-07-22 Xencor, Inc. Nouvelles immunoadhésines ctla4-ig
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (fr) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Anticorps se liant au csf1r
EP2580238A1 (fr) 2010-06-09 2013-04-17 Zymogenetics, Inc. Protéines de fusion vstm3 dimères et compositions et procédés connexes
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012087928A2 (fr) 2010-12-20 2012-06-28 The Rockefeller University Modulation d'anticorps agonistes anti-tnfr
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
EP3415528B1 (fr) 2011-04-13 2021-05-26 Bristol-Myers Squibb Company Protéines de fusion fc comprenant de nouveaux lieurs et arrangements
NO2694640T3 (fr) 2011-04-15 2018-03-17
CA2833636A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
US20130149300A1 (en) 2011-09-27 2013-06-13 Icon Genetics Gmbh MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
EA201892339A3 (ru) 2011-12-19 2019-06-28 Дзе Рокфеллер Юниверсити Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
SG11201405059XA (en) * 2012-03-28 2014-09-26 Kymab Ltd Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RS58801B1 (sr) 2012-09-13 2019-07-31 Bristol Myers Squibb Co Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
WO2014089169A2 (fr) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunothérapie par des agents de liaison
GB201308658D0 (en) 2013-05-14 2013-06-26 Isis Innovation Antibodies
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
SG11201601283PA (en) 2013-08-22 2016-03-30 Queensland Inst Med Res Immunoreceptor modulation for treating cancer and viral infections
WO2015143343A2 (fr) * 2014-03-21 2015-09-24 The Brigham And Women's Hospital, Inc. Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique
MX2016017288A (es) 2014-07-16 2017-06-27 Genentech Inc Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
CA2957722C (fr) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anticorps anti-tigit
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
SG10202007764TA (en) 2015-09-25 2020-09-29 Genentech Inc Anti-tigit antibodies and methods of use

Also Published As

Publication number Publication date
US10189902B2 (en) 2019-01-29
CN110256558B (zh) 2023-07-04
US20210324072A1 (en) 2021-10-21
EA039219B1 (ru) 2021-12-20
CN107207594A (zh) 2017-09-26
MA40662B1 (fr) 2020-12-31
CA2971732A1 (fr) 2016-06-30
MX2021012074A (es) 2021-11-03
AU2015369683A1 (en) 2017-08-10
EA201791171A1 (ru) 2017-11-30
CO2017006989A2 (es) 2018-01-05
IL285287B1 (en) 2023-03-01
JP2025128184A (ja) 2025-09-02
JP2021177759A (ja) 2021-11-18
SG11201705063VA (en) 2017-07-28
AU2015369683C1 (en) 2024-06-20
EP3237448A1 (fr) 2017-11-01
BR112017013385A2 (pt) 2018-02-06
MY187045A (en) 2021-08-27
US20160176963A1 (en) 2016-06-23
PH12022550771A1 (en) 2023-02-27
AU2021201231A1 (en) 2021-03-11
US11008390B2 (en) 2021-05-18
CN110256558A (zh) 2019-09-20
AU2021201231B2 (en) 2024-02-22
CN116731176A (zh) 2023-09-12
PH12017501166A1 (en) 2017-12-11
IL253013B (en) 2021-08-31
US20190112375A1 (en) 2019-04-18
SG10202006538TA (en) 2020-08-28
KR102644115B1 (ko) 2024-03-05
TW201629102A (zh) 2016-08-16
MX389267B (es) 2025-03-20
MX2017007744A (es) 2017-09-05
PH12017501166B1 (en) 2017-12-11
PE20171244A1 (es) 2017-08-24
WO2016106302A9 (fr) 2017-06-22
TWI708786B (zh) 2020-11-01
JP2017520512A (ja) 2017-07-27
JP2020062026A (ja) 2020-04-23
WO2016106302A1 (fr) 2016-06-30
IL253013A0 (en) 2017-08-31
JP6180663B2 (ja) 2017-08-16
US12060421B2 (en) 2024-08-13
UY36471A (es) 2016-06-30
AR103268A1 (es) 2017-04-26
JP2018035138A (ja) 2018-03-08
CL2017001660A1 (es) 2018-03-23
IL285287A (en) 2021-09-30
AU2015369683B2 (en) 2020-12-10
EP4249066A3 (fr) 2023-11-22
KR20170099966A (ko) 2017-09-01
IL285287B2 (en) 2023-07-01
JP2023139046A (ja) 2023-10-03
JP6633032B2 (ja) 2020-01-22
CN107207594B (zh) 2019-05-07
ZA201806307B (en) 2022-03-30
EP4249066A2 (fr) 2023-09-27
ZA201704981B (en) 2019-08-28
TN2017000267A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
MA40662B1 (fr) Anticorps contre tigit
AR120515A2 (es) Conjugado de enzimas terapéuticas
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d'utilisation
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
BR112022003956A2 (pt) Anticorpos anti-cd73
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
BR112018072211A2 (pt) anticorpos anti tl1a e utilizações dos mesmos
EA201691482A1 (ru) Человеческие антитела к pd-1
MX2016013767A (es) Anticuerpos humanizados contra cd269 (bcma).
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
MX2016014210A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
EA201691541A1 (ru) Новые анти-baff антитела
EA201400447A1 (ru) АНТИТЕЛА К CD1d
MA38161A1 (fr) Anticorps anti-bmp-6
JOP20180121A1 (ar) أجسام مضادة ضد عامل التخثر xi
BR112017025496A2 (pt) Moléculas de ligação neutralizantes anti- influenza e usos das mesmas